Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.

Importance Despite many cases being preventable, cutaneous melanoma remains the most serious skin cancer worldwide. Understanding the scale and profile of the disease is vital to concentrate and reinforce global prevention efforts. Objective To examine global patterns of cutaneous melanoma in 2020 and to provide projected estimates of cases and deaths by 2040. Design, Setting, and Participants This population-based study used the GLOBOCAN 2020 database for global epidemiological assessment of new cases and deaths due to invasive melanoma. Main Outcomes and Measures Age-standardized incidence and mortality rates were calculated per 100 000 person-years by country, world region, and 4-tier level of human development. Estimated numbers of cases and deaths were calculated for the year 2040. Results A worldwide total of 325 000 new melanoma cases (174 000 males, 151 000 females) and 57 000 deaths (32 000 males, 25 000 females) was estimated for 2020. Large geographic variations existed across countries and world regions, with the highest incidence rates among males (42 per 100 000 person-years) and females (31 per 100 000 person-years) observed in Australia/New Zealand, followed by Western Europe (19 per 100 000 person-years for males and females), North America (18 per 100 000 person-years for males, 14 per 100 000 person-years for females), and Northern Europe (17 per 100 000 person-years for males, 18 per 100 000 person-years for females). Melanoma continued to be rare in most African and Asian countries, with incidence rates commonly less than 1 per 100 000 person-years. Mortality rates peaked at 5 per 100 000 person-years in New Zealand, and geographic variations were less pronounced than for incidence. Melanoma was more frequent among males than females in most world regions. If 2020 rates continue, the burden from melanoma is estimated to increase to 510 000 new cases (a roughly 50% increase) and to 96 000 deaths (a 68% increase) by 2040. Conclusions and Relevance This epidemiological assessment suggests that melanoma remains an important challenge to cancer control and public health globally, especially in fair-skinned populations of European descent.

[1]  C. Garbe,et al.  Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. , 2021, European journal of cancer.

[2]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[3]  V. Urbonas,et al.  Trends in Incidence and Mortality of Skin Melanoma in Lithuania 1991–2015 , 2021, International journal of environmental research and public health.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  H. Welch,et al.  The Rapid Rise in Cutaneous Melanoma Diagnoses. , 2021, The New England journal of medicine.

[6]  Human Development Report 2020 , 2020, Human Development Report.

[7]  A. Carè,et al.  Sex and Gender Disparities in Melanoma , 2020, Cancers.

[8]  M. Barclay,et al.  Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data , 2020, Melanoma research.

[9]  D. Whiteman,et al.  Evaluation of Sex-Specific Incidence of Melanoma. , 2020, JAMA dermatology.

[10]  Blair H. Smith,et al.  Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility , 2020, Nature Genetics.

[11]  J. Berk-Krauss,et al.  New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016. , 2020, American journal of public health.

[12]  H. Soyer,et al.  Long‐term deaths from melanoma according to tumor thickness at diagnosis , 2020, International journal of cancer.

[13]  D. Byrd,et al.  Age-Specific Incidence of Melanoma in the United States. , 2019, JAMA dermatology.

[14]  J. Larkin,et al.  Current and emerging systemic therapies for cutaneous metastatic melanoma , 2019, Expert opinion on pharmacotherapy.

[15]  J. Spicer,et al.  Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma , 2019, Front. Immunol..

[16]  A. Jemal,et al.  Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. , 2019, The Lancet. Public health.

[17]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[18]  A. Jemal,et al.  Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012 , 2018, International journal of cancer.

[19]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[20]  A. Gavin,et al.  Trends in incidence of thick, thin and in situ melanoma in Europe. , 2018, European journal of cancer.

[21]  J. Ferlay,et al.  Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. , 2017, The Lancet. Oncology.

[22]  D. Rigel,et al.  Analysis of Trends in US Melanoma Incidence and Mortality , 2017, JAMA dermatology.

[23]  M. Weinstock,et al.  Melanoma burden and recent trends among non-Hispanic whites aged 15-49years, United States. , 2016, Preventive medicine.

[24]  D. Forman,et al.  The burden of cutaneous melanoma and status of preventive measures in Central and South America. , 2016, Cancer epidemiology.

[25]  D. Whiteman,et al.  The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. , 2016, The Journal of investigative dermatology.

[26]  W. Mooi,et al.  Increasing time trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations? , 2015, European journal of cancer.

[27]  C. Bain,et al.  Cancers in Australia attributable to exposure to solar ultraviolet radiation and prevented by regular sunscreen use , 2015, Australian and New Zealand journal of public health.

[28]  P. Baade,et al.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. , 2015, The Journal of investigative dermatology.

[29]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[30]  M. Iannacone,et al.  Towards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in Australia. , 2014, Melanoma management.

[31]  J. Coebergh,et al.  Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015 , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  J. Lortet-Tieulent,et al.  International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? , 2013, International journal of cancer.

[33]  M A Weinstock,et al.  Skin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population-based screening , 2012, British Journal of Cancer.

[34]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[35]  Kurt Straif,et al.  A review of human carcinogens--part D: radiation. , 2009, The Lancet. Oncology.

[36]  M. Nicolson,et al.  Melanoma incidence and mortality in Scotland 1979–2003 , 2007, British Journal of Cancer.

[37]  S. Puig,et al.  High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. , 2006, Cancer research.

[38]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. , 2005, European journal of cancer.

[39]  R. Gallagher,et al.  Etiologic and Other Factors Predicting Nevus-Associated Cutaneous Malignant Melanoma , 2005, Cancer Epidemiology Biomarkers & Prevention.

[40]  C. Ingvar,et al.  Invasive cutaneous malignant melanoma in Sweden, 1990–1999 , 2004, Cancer.

[41]  J. Coebergh,et al.  Cutaneous malignant melanoma in Europe. , 2004, European journal of cancer.

[42]  F. Bray,et al.  Practical implications of imposing a new world standard population , 2002, Cancer Causes & Control.

[43]  Ian Jackson,et al.  Variants of the melanocyte–stimulating hormone receptor gene are associated with red hair and fair skin in humans , 1995, Nature Genetics.

[44]  B. Armstrong,et al.  How much melanoma is caused by sun exposure? , 1993, Melanoma research.

[45]  Alexander Katalinic,et al.  Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review , 2017, Journal of the American Academy of Dermatology.

[46]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[47]  J. Aitken,et al.  Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990–2006 , 2012, International journal of cancer.

[48]  R. Sankaranarayanan,et al.  Cancer survival in Africa, Asia, the Caribbean and Central America: database and attributes. , 2011, IARC scientific publications.

[49]  F. Bray,et al.  Predicting the future burden of cancer , 2006, Nature Reviews Cancer.

[50]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[51]  N. Day Cancer Incidence in Five Continents. Cumulative rate and cumulative risk. , 1992, IARC scientific publications.

[52]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  Jacques Ferlay,et al.  Cancer incidence in five continents. , 1976, IARC scientific publications.

[54]  Richard Doll,et al.  Cancer incidence in five continents : a technical report , 1966 .